{"id":48,"count":6,"description":"<div class=\"scroll-box\">\r\n<h2 style=\"text-align: center\">Utforska GLP-1-peptider: Forskningsapplikationer inom metabolism och aptitreglering<\/h2>\r\n<em>GLP-1-peptider \u00e4r en kategori av forskningsf\u00f6reningar som studeras f\u00f6r sina effekter p\u00e5 blodsockerreglering, aptitd\u00e4mpning och metabol balans. Dessa peptider efterliknar eller f\u00f6rst\u00e4rker verkan av glukagon liknande peptid-1, ett hormon som spelar en central roll f\u00f6r glukoshomeostas och energiintag. I laboratoriemilj\u00f6er unders\u00f6ks GLP-1-peptider ofta f\u00f6r sin potential inom modeller f\u00f6r fetma, typ 2-diabetes och vikthantering. <\/em>\r\n\r\nGLP-1 peptides are a class of research compounds that mimic or enhance the activity of glucagon-like peptide-1, a hormone involved in appetite control, insulin secretion, and glucose metabolism. In scientific studies, these peptides are explored for their ability to suppress hunger, promote fat loss, and regulate blood sugar levels, making them a major focus in research targeting obesity, type 2 diabetes, and other metabolic disorders.\r\n\r\nGLP-1 receptor agonists work by activating incretin pathways (GLP-1, GIP, and glucagon receptors), which collectively help improve insulin sensitivity, slow gastric emptying, reduce food intake, and increase metabolic expenditure. More advanced compounds in this class also target multiple receptors to enhance metabolic effects, offering new possibilities for studying complex weight-related mechanisms in lab settings.\r\n\r\n<em><strong>Ansvarsfriskrivning: <\/strong>Alla GLP-1-peptider som refereras till h\u00e4r \u00e4r endast avsedda f\u00f6r laboratorieforskning. Eventuella humanrelaterade resultat som n\u00e4mns baseras enbart p\u00e5 fynd fr\u00e5n djurmodeller eller kliniska data och ska inte tolkas som medicinsk r\u00e5dgivning eller terapeutiska rekommendationer.<\/em>\r\n<h2>Vad \u00e4r GLP-1-receptoragonistpeptider?<\/h2>\r\nGLP-1 receptor agonist peptides are synthetic compounds designed to replicate or enhance the effects of glucagon-like peptide-1 (GLP-1), an incretin hormone released by the gut after eating. In research settings, GLP-1 is known for its ability to stimulate insulin secretion, suppress appetite, slow gastric emptying, and regulate blood sugar. However, the natural hormone breaks down quickly in the body, prompting the development of longer-lasting analogs for laboratory use.\r\n\r\nModern GLP-1 peptides are engineered for increased stability and often include multi-receptor activity. In addition to GLP-1 activation, some of these peptides also target:\r\n<ul>\r\n \t<li><strong>GIP (glukosberoende insulinotropt polypeptid):<\/strong> \u00d6kar insulinfris\u00e4ttningen och p\u00e5verkar fettmetabolismen<\/li>\r\n \t<li><strong>Glukagonreceptorer:<\/strong> Fr\u00e4mjar fettf\u00f6rbr\u00e4nning, termogenes och energif\u00f6rbrukning<\/li>\r\n<\/ul>\r\nDessa kombinerade effekter g\u00f6r GLP-1-receptoragonister v\u00e4rdefulla i prekliniska forskningsmodeller med fokus p\u00e5:\r\n<ul>\r\n \t<li>Viktminskning och aptitd\u00e4mpning<\/li>\r\n \t<li>Fetma och metabola syndromet<\/li>\r\n \t<li>Insulind resist\u00eancia och glukoshomeostas<\/li>\r\n \t<li>Studier av fettmassa och energibalans<\/li>\r\n<\/ul>\r\nPeptider som semaglutid, tirzepatid och retatrutid anv\u00e4nds ofta i denna forskningskategori f\u00f6r sina kraftfulla metabola och viktreducerande effekter.\r\n<h2>Verkningsmekanismer f\u00f6r GLP-1-peptider<\/h2>\r\nGLP-1 receptor agonist peptides work by mimicking or enhancing natural gut hormones that regulate hunger, insulin release, and energy metabolism. Each peptide in this category acts on different combinations of receptors to drive metabolic effects. Here's a breakdown of the mechanisms by individual peptide:\r\n\r\n<strong>Semaglutid<\/strong>\r\n<ul>\r\n \t<li>Semaglutid \u00e4r en GLP-1-receptoragonist som efterliknar naturliga inkretinhormoner.<\/li>\r\n \t<li>Det s\u00e4nker mags\u00e4ckst\u00f6mningen, vilket f\u00f6rl\u00e4nger m\u00e4ttnadsk\u00e4nslan och minskar kaloriintaget.<\/li>\r\n \t<li>\u00d6kar insulinfris\u00f6rjningen som svar p\u00e5 glukos och s\u00e4nker blodsockerniv\u00e5erna.<\/li>\r\n \t<li>Dess l\u00e5ngverkande design st\u00f6der dosering en g\u00e5ng i veckan i forskningsmodeller och uppr\u00e4tth\u00e5ller en stabil receptoraktivering \u00f6ver tid.<\/li>\r\n<\/ul>\r\n<strong>Tirzepatid<\/strong>\r\n<ul>\r\n \t<li>En dubbel agonist f\u00f6r b\u00e5de GLP-1- och GIP-receptorer (glukosberoende insulinotropppolypeptid).<\/li>\r\n \t<li>F\u00f6rb\u00e4ttrar insulink\u00e4nsligheten och -sekretionen samtidigt som den modulerar glukagonniv\u00e5erna.<\/li>\r\n \t<li>D\u00e4mpar aptiten kraftigt och f\u00f6rb\u00e4ttrar den glykemiska kontrollen, vilket leder till m\u00e4rkbar viktnedg\u00e5ng.<\/li>\r\n \t<li>I SURPASS-kliniska studier presterade tirzepatid b\u00e4ttre \u00e4n semaglutid n\u00e4r det g\u00e4llde att minska kroppsvikt och blodsocker.<\/li>\r\n<\/ul>\r\n<strong>Retatrutid<\/strong>\r\n<ul>\r\n \t<li>En trippelreceptoragonist som riktar sig mot GLP-1-, GIP- och glukagonreceptorer.<\/li>\r\n \t<li>Aktiverar glukagonv\u00e4gar f\u00f6r att \u00f6ka energif\u00f6rbrukningen och den basala \u00e4mnesoms\u00e4ttningen.<\/li>\r\n \t<li>Det fr\u00e4mjar lipolys och fettoxidation, vilket g\u00f6r det till en av de mest potenta peptiderna som har studerats f\u00f6r minskning av kroppsfett.<\/li>\r\n \t<li>Tidiga studier p\u00e5 m\u00e4nniskor visar st\u00f6rre viktnedg\u00e5ng \u00e4n andra GLP-1-baserade preparat.<\/li>\r\n<\/ul>\r\nTillsammans utg\u00f6r dessa peptider en kraftfull klass av metaboliska regulatorer i laboratoriestudier, vilket ger insikt i aptitkontroll, insulindynamik och energibalans.\r\n<h2>Forskning och kliniska fynd<\/h2>\r\nGLP-1-peptider som semaglutid, tirzepatid och retatrutid has omformat metabol forskning p\u00e5 grund av deras kraftfulla effekter p\u00e5 viktnedg\u00e5ng, aptitreglering och glukoskontroll. Var och en har studerats i omfattande kliniska och laboratoriem\u00e4ssiga pr\u00f6vningar, med konsekvent starka resultat:\r\n<h3>Semaglutid<\/h3>\r\n<ul>\r\n \t<li>I de kliniska STEP-studierna gick \u00f6verviktiga personer utan diabetes ner i vikt med i genomsnitt ~15% under 68 veckor.<\/li>\r\n \t<li>Betydande minskningar observerades ocks\u00e5 i midjem\u00e5tt, fastande insulin och inflammatoriska biomark\u00f6rer.<\/li>\r\n \t<li>Deltagarna rapporterade aptitd\u00e4mpning inom n\u00e5gra dagar, vilket f\u00f6rb\u00e4ttrade f\u00f6ljsamheten i l\u00e5ngtidsforskningsprotokoll.<\/li>\r\n<\/ul>\r\n<h3>Tirzepatid<\/h3>\r\n<ul>\r\n \t<li>SURMOUNT-1-studien visade en viktminskning p\u00e5 cirka 22,51 TP3T under 72 veckor.<\/li>\r\n \t<li>Tirzepatid f\u00f6rb\u00e4ttrade \u00e4ven HbA1c-niv\u00e5er, insulink\u00e4nslighet och lipidprofiler.<\/li>\r\n \t<li>Dess dubbla GIP- och GLP-1-aktivitet gjorde den \u00f6verl\u00e4gsen enbart GLP-1-agonister i direkt j\u00e4mf\u00f6rande studier.<\/li>\r\n \t<li>Forskning visar f\u00f6rdelar i b\u00e5de diabetiska och icke-diabetiska metabola modeller.<\/li>\r\n<\/ul>\r\n<h3>Retatrutid<\/h3>\r\n<ul>\r\n \t<li>En fas II-studie (2023) visade en fettf\u00f6rlust p\u00e5 upp till 24,21 TP3T hos deltagare med \u00f6vervikt eller fetma, vilket \u00e4r den h\u00f6gsta siffran som hittills observerats inom inkretinklassen.<\/li>\r\n \t<li>Genom aktivering av glukagonreceptorn \u00f6kade den energif\u00f6rbrukningen och fettoxidationen ut\u00f6ver enbart GLP-1\/GIP-mekanismerna.<\/li>\r\n \t<li>Visade \u00e4ven f\u00f6rdelar n\u00e4r det g\u00e4ller blodtryck, triglycerider och fettinneh\u00e5ll i levern.<\/li>\r\n<\/ul>\r\n<strong>\u00d6vergripande insikter<\/strong>\r\n\r\nAlla tre pepiderna visar konsekvent:\r\n<ul>\r\n \t<li>Snabb aptitd\u00e4mpning<\/li>\r\n \t<li>Minskad fettmassa, midjeomf\u00e5ng och fastande insulin<\/li>\r\n \t<li>F\u00f6rb\u00e4ttrade kardiometabola mark\u00f6rer (kolesterol, blodtryck, CRP)<\/li>\r\n \t<li>L\u00e5nga halveringstider g\u00f6r dem idealiska f\u00f6r veckovis eller varannan vecka f\u00f6rekommande forskningsdoseringsregler<\/li>\r\n<\/ul>\r\nDessa fynd har bef\u00e4st GLP-1-receptoragonister som h\u00f6rnstensf\u00f6reningar inom fetma- och metabol forskning.\r\n<h2>Insikter om s\u00e4kerhet och regleringar<\/h2>\r\nGLP-1 peptide research continues to evolve, with several compounds already approved for clinical use and others in advanced trial phases:\r\n\r\nSemaglutide is FDA-approved for both type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). It is widely studied in metabolic models and has a well-documented safety profile in both diabetic and non-diabetic populations.\r\n\r\nTirzepatide, a dual GLP-1\/GIP agonist, is also FDA-approved for type 2 diabetes (as Mounjaro) and is under review for obesity-related approvals, following positive SURMOUNT trial data.\r\n\r\nRetatrutide, the triple agonist (GLP-1, GIP, glucagon), remains investigational but has shown groundbreaking results in Phase II trials, with potential to become a new class leader in fat loss and metabolic support research.\r\n\r\n<strong>Vanligt f\u00f6rekommande effekter som observerats i forskning inkluderar:<\/strong>\r\n<ul>\r\n \t<li>Illam\u00e5ende<\/li>\r\n \t<li>F\u00f6rstoppning<\/li>\r\n \t<li>Aptitd\u00e4mpning<\/li>\r\n \t<li>Dessa \u00e4r typiskt dosberoende och minskar \u00f6ver tid i l\u00e5ngtidsstudier.<\/li>\r\n<\/ul>\r\n<strong>Anv\u00e4ndarriktlinjer:<\/strong>\r\n<ul>\r\n \t<li>Till\u00e4mpa i kontrollerade laboratoriemilj\u00f6er med fokus p\u00e5 fetma, insulinresistens eller energimetabolism.<\/li>\r\n \t<li>Uppr\u00e4tth\u00e5ll steril teknik, kylkedjef\u00f6rvaring och protokolldokumentation f\u00f6r reproducerbarhet.<\/li>\r\n<\/ul>\r\n<strong>Viktig p\u00e5minnelse:<\/strong>\r\n\r\nAlla peptider som diskuteras \u00e4r strikt avsedda endast f\u00f6r laboratorieforskning. De \u00e4r inte godk\u00e4nda f\u00f6r administrering till m\u00e4nniskor, s\u00e5vida det inte sker inom ramen f\u00f6r reglerade kliniska pr\u00f6vningar eller receptf\u00f6rskrivning.\r\n<h2>B\u00e4sta GLP-1-peptiderna f\u00f6r forskning<\/h2>\r\nGLP-1-peptider har revolutionerat den metabolika och fetmarelaterade forskningen. F\u00f6ljande peptider utm\u00e4rker sig genom sin v\u00e4l dokumenterade effekt i prekliniska och kliniska modeller:\r\n<ul>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/sv\/product\/buy-semaglutide-5mg\/\"><strong>Semaglutid<\/strong><\/a> \u2013 En v\u00e4l unders\u00f6kt GLP-1-receptoragonist som \u00e4r k\u00e4nd f\u00f6r sin roll n\u00e4r det g\u00e4ller aptitd\u00e4mpning, glukosreglering och minskning av fettmassa. Den har visat sig ge en konsekvent viktminskning p\u00e5 ~15% i l\u00e5ngsiktiga studier av fetma.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/sv\/product\/buy-tirzepatide-5mg\/\"><strong>Tirzepatid<\/strong><\/a> \u2013 En dubbel GLP-1\/GIP-agonist som f\u00f6rb\u00e4ttrar insulink\u00e4nsligheten och minskar kroppsvikten \u00e4nnu effektivare \u00e4n semaglutid. Kliniska studier som SURMOUNT-1 visade en genomsnittlig viktminskning p\u00e5 22,5% hos de behandlade f\u00f6rs\u00f6kspersonerna.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/sv\/product\/buy-retatrutide-5mg\/\"><strong>Retatrutid<\/strong><\/a> \u2013 En tredubbel agonist av n\u00e4sta generation som riktar sig mot GLP-1-, GIP- och glukagonreceptorer. Tidiga studier visar en fettf\u00f6rbr\u00e4nning p\u00e5 upp till 24,2%, vilket g\u00f6r den till en av de mest potenta peptiderna inom den aktuella forskningen om fetma.<\/li>\r\n<\/ul>\r\n<h2>Laboratorieanv\u00e4ndning och rekonstituering<\/h2>\r\nGLP-1-peptider som semaglutid, tirzepatid och retatrutid m\u00e5ste rekonstitueras och hanteras p\u00e5 ett korrekt s\u00e4tt under sterila laboratorief\u00f6rh\u00e5llanden f\u00f6r att uppr\u00e4tth\u00e5lla stabilitet och noggrannhet i forskningen.\r\n\r\n<strong>Rekonstitution<\/strong>De flesta GLP-1-peptider kan rekonstitueras med bakteriostatiskt vatten eller steril koksaltl\u00f6sning. Spruta f\u00f6rsiktigt in l\u00f6sningen l\u00e4ngs flaskans innerv\u00e4gg f\u00f6r att undvika skumbildning, och snurra den f\u00f6rsiktigt tills den \u00e4r helt uppl\u00f6st.\r\n\r\n<strong>Lagring<\/strong>:\r\n<ul>\r\n \t<li>Frystorkade peptider kan f\u00f6rvaras i rumstemperatur och skyddas mot ljus.<\/li>\r\n \t<li>Rekonstituerade peptider f\u00f6rblir stabila i 30\u201360+ dagar vid kylf\u00f6rvaring i 2\u20138 \u00b0C.<\/li>\r\n<\/ul>\r\n<strong>Doseringsanvisningar i prekliniska modeller:<\/strong>\r\n\r\nStandarddosen varierar fr\u00e5n 0,01\u20130,2 mg\/kg hos m\u00f6ss eller r\u00e5ttor, beroende p\u00e5 det experimentella uppl\u00e4gget och forskningsm\u00e5len.\r\n<h3>Vanliga forskningsm\u00e5l:<\/h3>\r\n<ul>\r\n \t<li>Kroppsvikt \u00f6ver tid<\/li>\r\n \t<li>Aptitd\u00e4mpning och \u00f6vervakning av matintag<\/li>\r\n \t<li>glukostoleranstester<\/li>\r\n \t<li>Analys av fettkuddsmassa och sammans\u00e4ttning<\/li>\r\n \t<li>Aktivitet hos inkretinhormoner, inklusive analyser av insulin, GLP-1, GIP och glukagon<\/li>\r\n<\/ul>\r\nDessa peptider \u00e4r uteslutande avsedda f\u00f6r laboratorieforskning, and all hantering b\u00f6r f\u00f6lja etiska protokoll och sterila best practices.\r\n<h2>Vanliga fr\u00e5gor<\/h2>\r\n<h3>Vilken GLP-1-peptid ger st\u00f6rst fettf\u00f6rlust?<\/h3>\r\nRetatrutid har visat sig ge den mest markanta viktminskningen (~24%) i tidiga kliniska pr\u00f6vningar.\r\n<h3>Kan peptider kombineras f\u00f6r b\u00e4ttre resultat?<\/h3>\r\nVanligtvis inte. Retatrutid aktiverar redan GLP-1-, GIP- och glukagonreceptorer, vilket g\u00f6r ytterligare kombinationer (stacking) on\u00f6diga.\r\n<h3>Vad b\u00f6r jag g\u00f6ra om en peptid inte l\u00f6ser sig helt?<\/h3>\r\nSnurra f\u00f6rsiktigt p\u00e5 injektionsflaskan, skaka inte. L\u00e4tt uppv\u00e4rmning (i ett 37 \u00b0C vattenbad) kan underl\u00e4tta uppl\u00f6sningen.\r\n<h3>Finns det skillnader i receptoraffinitet mellan dessa peptider?<\/h3>\r\nYes. Semaglutide selectively targets GLP-1 receptors, while Tirzepatide and Retatrutide act on multiple receptors for a broader effect.\r\n\r\nTo finish up, GLP-1 peptides represent a leading edge in metabolic research, offering compelling avenues to study fat loss, insulin regulation, and appetite suppression. Peptides such as Semaglutide, Tirzepatide, and Retatrutide have shown significant effects in both preclinical and clinical models, making them valuable tools for obesity and diabetes-related investigations.\r\n\r\nExplore the full GLP-1 peptide catalog at CellPeptides to support your next metabolic research project.\r\n\r\n<\/div>","link":"https:\/\/cellpeptides.com\/sv\/purpose\/glp-1-peptides\/","name":"GLP-1-forskningspeptider","slug":"glp-1-peptides","taxonomy":"product_cat","parent":0,"meta":[],"menu_order":0,"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides<\/title>\n<meta name=\"description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cellpeptides.com\/sv\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\" \/>\n<meta property=\"og:description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cellpeptides.com\/sv\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:site_name\" content=\"CellPeptides\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"CollectionPage\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"url\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"name\":\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\",\"isPartOf\":{\"@id\":\"https:\/\/cellpeptides.com\/#website\"},\"description\":\"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU\",\"breadcrumb\":{\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\"},\"inLanguage\":\"sv-SE\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cellpeptides.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GLP-1 Research Peptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cellpeptides.com\/#website\",\"url\":\"https:\/\/cellpeptides.com\/\",\"name\":\"CellPeptides\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/cellpeptides.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cellpeptides.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cellpeptides.com\/#organization\",\"name\":\"CellPeptides\",\"url\":\"https:\/\/cellpeptides.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"contentUrl\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"width\":697,\"height\":152,\"caption\":\"CellPeptides\"},\"image\":{\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"K\u00f6p GLP-1-peptider f\u00f6r metabola studier (in vitro) \u2013 CellPeptides","description":"K\u00f6p GLP-1-receptoragonister f\u00f6r aptit-, glukos- och metabolisk forskning \u2013 Semaglutid, Tirzepatid, Retatrutid. Snabb frakt i USA och EU","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cellpeptides.com\/sv\/purpose\/glp-1-peptides\/","og_locale":"sv_SE","og_type":"article","og_title":"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides","og_description":"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU","og_url":"https:\/\/cellpeptides.com\/sv\/purpose\/glp-1-peptides\/","og_site_name":"CellPeptides","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"CollectionPage","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","url":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","name":"K\u00f6p GLP-1-peptider f\u00f6r metabola studier (in vitro) \u2013 CellPeptides","isPartOf":{"@id":"https:\/\/cellpeptides.com\/#website"},"description":"K\u00f6p GLP-1-receptoragonister f\u00f6r aptit-, glukos- och metabolisk forskning \u2013 Semaglutid, Tirzepatid, Retatrutid. Snabb frakt i USA och EU","breadcrumb":{"@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb"},"inLanguage":"sv-SE"},{"@type":"BreadcrumbList","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cellpeptides.com\/"},{"@type":"ListItem","position":2,"name":"GLP-1 Research Peptides"}]},{"@type":"WebSite","@id":"https:\/\/cellpeptides.com\/#website","url":"https:\/\/cellpeptides.com\/","name":"CellPeptides","description":"","publisher":{"@id":"https:\/\/cellpeptides.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cellpeptides.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/cellpeptides.com\/#organization","name":"CellPeptides","url":"https:\/\/cellpeptides.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/","url":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","contentUrl":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","width":697,"height":152,"caption":"CellPeptides"},"image":{"@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cellpeptides.com\/sv\/wp-json\/wp\/v2\/product_cat\/48","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cellpeptides.com\/sv\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/cellpeptides.com\/sv\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"wp:post_type":[{"href":"https:\/\/cellpeptides.com\/sv\/wp-json\/wp\/v2\/product?product_cat=48"}],"curies":[{"name":"WP","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}